The UAE’s Ministry of Health and Prevention (MoHAP) has recently approved the registration and use of Amgen’s lung cancer drug Lumakras, following the approval of the US Food and Drug Administration, Emirates News Agency (WAM) reported.
This will provide lung cancer patients early access to this innovative drug to help speed up their treatment plan and improve the quality of their life, WAM said.
The registration comes because of the application of MoHAP’s innovative mechanism for its accelerators to evaluate and approve the world’s breakthrough drugs following the Fast Track/Accelerate Process system.
LUMAKRAS is supplied as a film-coated tablet for oral use containing 120mg of Sotorasib. The drug is prescribed to adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy, said WAM.
Dr. Mohammed Salim Al Olama, MoHAP Under-Secretary and Head of Board of Directors of the Emirates Health Services (EHS), said that the ministry, under the guidance of the wise leadership, is keen to further consolidate the UAE’s position in the global pharmaceutical market.
Al Olama underlined that the flexible legislative environment has stimulated the global pharmaceutical companies to choose the country as a hub for marketing and promoting their new and innovative products, which gives solutions to patients in the country and region.